Hafid De Ruben Calderon Huaycochea

Hafid De Ruben Calderon Huaycochea

Auto-generated profile, based on publicly available information

Hafid De Ruben Calderon Huaycochea

Universidad Científica del Sur, Lima, Perú

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JCO Global Oncology
Verified
Journal Article
Open access
BVBryan Valcarcel
Bryan Valcarcel
DEDaniel Enriquez-Vera
Daniel Enriquez-Vera
GKGabriel De la Cruz Ku
Gabriel De la Cruz Ku
DCDiego Chambergo-Michilot
Diego Chambergo-Michilot
HCHafid Calderón-Huaycochea
Hafid Calderón-Huaycochea
LMLuis Malpica
Luis Malpica
PURPOSE: Human T-lymphotropic virus type 1 (HTLV-1) is an endemic virus in Latin America that is directly linked to adult T-cell leukemia/lymphoma (ATL). Previous studies have suggested an oncogenic role of HTLV-1 in non-ATL neoplasms and have found higher mortality in HTLV-1 carriers without ATL. METHODS: In this retrospective cohort study, HTLV-1 carriers were identified through screening at a tertiary cancer center between 2006 and 2019. We compared the overall survival (OS) outcomes of patients with ATL with those with other solid or hematologic malignancies by sex stratification. RESULTS: We identified 1,934 HTLV-1 carriers diagnosed with cancer. The median age at diagnosis was 62 (range 20-114) years, 76% were female, 60% had no or elementary school education, and 50% were born in the Andean highlands. The most common non-ATL neoplasm was cervical cancer (50%) among females and non-ATL non-Hodgkin lymphoma (26%) among males. With a median follow-up of 66 months, the 5-year OS of HTLV-1 carriers with non-ATL neoplasms (26%-47% for females and 22%-34% for males) was inferior to those reported in the general population. As expected, patients with ATL had a worse prognosis (5-year OS: 10% for females and 8% for males). CONCLUSION: HTLV-1 carriers with cancer were middle age and from underprivileged settings, suggesting an undetected transmission among vulnerable populations, especially females. Survival estimates of HTLV-1 carriers with non-ATL neoplasms were lower than the regional outcomes. Future research should ascertain how the biology of HTLV-1 and health care disparities affect the outcomes of HTLV-1 carriers, as well as determine the burden of HTLV-1 infection in the cancer population to recommend screening in the outpatient setting of endemic regions.

16 June 2022
Verified
Thesis
Open access
CGChristian Gonzales Gavancho
Christian Gonzales Gavancho
HHHafid De Ruben Calderon Huaycochea
Hafid De Ruben Calderon Huaycochea
Introducción: la Leucemia linfoblástica aguda (LLA) presenta una supervivencia global (SG) en infantes y adultos de 90% y 20-40% respectivamente a 5 años. La alteración citogenética más frecuente, de peor pronóstico y con alta mortalidad, es el cromosoma filadelfia (Ph). Este estudio tiene como objetivo determinar la supervivencia en pacientes con LLA Ph positivo (Ph+). Métodos: Realizamos una cohorte retrospectiva. Todos los pacientes con criterios anatomopatológicos para el diagnóstico de LLA Ph+ fueron incluidos. Las variables laboratoriales fueron recolectadas de historias clínicas electrónicas. SG fue definida como los meses desde el diagnóstico de LLA Ph+ hasta la muerte por cualquier causa. Resultados: la SG fue 12.03% (IC 95% = 3.69 - 25.68) a 9 años, una mediana de supervivencia de 15 meses (Q1 8 - Q2 41), una supervivencia a 5 años de 20.39% (IC 95% = 11.52 - 31.04). De 135 pacientes; 90 (66,67%) tenían <40 años, 45 (33.33%) eran ≥ 40 años, la mediana de supervivencia para los ≥40 años fue 5 meses (Q1 1 - Q3 26; p<0.005). De 91 pacientes, se encontró enfermedad mínima residual (EMR) positiva a 50 (54.9%), la mediana de supervivencia fue 13 meses (Q1 7 - Q3 33; p<0.005). Conclusiones: La SG de LLA Ph+ en nuestra población fue inferior a lo reportado en Asia, Europa y América. Estos resultados servirán para mejorar el suministro de insumos, importancia del tratamiento y disminuir la morbimortalidad tan alta que presenta la LLA Ph+ en el Perú.